OSLO/LONDON, MARCH 1st 2021: EXACT THERAPEUTICS AS ("EXACT-Tx" or the
"Company"), a clinical stage precision medicine company today announced that its
proprietary Acoustic Cluster Therapy (ACT®) platform technology for targeted
therapeutic enhancement will be the subject of a presentation at the forthcoming
ESMO Targeted Anticancer Therapies (TAT) Virtual Congress 2021. 

The ESMO Targeted Anticancer Therapies Virtual Congress 2021 is set to offer
participants a glimpse of the future of targeted anticancer therapies and is the
premier international meeting focusing on promising new anticancer targets and
agents, with a particular focus on those in early phase clinical development. 

The presentation will take place on March 1st 2021 and will focus on the
background and rationale of ACT®, preclinical study data and the ongoing Phase I
evaluation. The Phase I ACTIVATE study is evaluating the safety, tolerability,
pharmacokinetics and pharmacodynamics of ACT® when co-administered with standard
of care chemotherapy in patients with metastatic colorectal cancer. 


Title: Acoustic cluster therapy (ACT) as a mechanism of increasing drug
delivery: Phase I experience (ID50)

Presenting Author: Prof Udai Banerji, NIHR Professor of Molecular Cancer
Pharmacology and Honorary Consultant in Medical Oncology, Royal Marsden
Hospital, London.

Session: (Educational) Nothing is undruggable! (ID19)

Date/Time: Monday 1st March 2021/ 13.00-13.15

The Targeted Anticancer Therapies 2021 Virtual Congress 2021 will bring together
experts in anticancer drug discovery and clinical development, translational
scientists, and regulators in a unique forum to highlight recent advances and
new data, whilst promoting collaboration and knowledge-sharing in a
bench-to-bedside approach. The TAT meeting is a meeting focused on early
clinical trials and has been described as 'The home of phase I in oncology'.
This meeting will be entirely dedicated to improving the conduct of early
anti-cancer clinical trials, with presentations, discussions and educational
reviews and workshops highlighting emerging pre-clinical and clinical data, as
well as defining optimal methodologies for early clinical trials. 

About ACT®
o ACT® is a proprietary formulation consisting of microbubbles and microdroplets
that are activated through the application of ultrasound with the consequent
increase in targeted delivery of a co-administered therapeutic agent. 
o ACT® is supported by a strong and broad preclinical package demonstrating
therapeutic enhancement in multiple oncology models (pancreatic, breast, colon,
prostate) as well as blood-brain barrier penetration.
o Initial focus of the company is oncology, however the ACT® platform has
potential across therapeutic areas (infectious diseases, CNS, immunotherapy) and
product classes.


About EXACT
EXACT-Tx is a clinical stage Norwegian biotech company developing a technology
platform for targeted therapeutic enhancement - Acoustic Cluster Therapy (ACT®).
ACT® sonoporation is a unique approach to ultrasound-mediated, targeted drug
enhancement - with the potential to significantly amplify the clinical utility
of a wide range of therapeutic agents across a multitude of indications
including within oncology (chemotherapy, immunotherapy), infectious diseases,
and neurological conditions. www.exact-tx.com

For more information contact:
Dr Rafiq Hasan, 
CEO EXACT Therapeutics
Rafiq@exact-tx.com

Richard Hayhurst/Janet Joy
Tel +44 7711 821527
richard@rhapr.eu